Genentech’s phase III EMPACTA study showed Actemra reduced the likelihood of needing mechanical ventilation in hospitalized patients with COVID-19 associated pneumonia.- Genentech/Roche
ChemoCentryx announces FDA acceptance of the avacopan NDA for the treatment of ANCA-associated vasculitis.
Phase III CheckMate -214 trial of Yervoy + Opdivo shows sustained benefits and four year survival rate in advanced renal cell carcinoma.- BMS
Real-world study of Nerivio Migra in migraine published in Pain Medicine.- Theranica
Phase Ib/II trial of PCM 075 shows efficacy in metastatic KRAS colorectal cancer.- Cardiff Oncology
FDA expands approval of CINtec PLUS Cytology test in HPV-positive patients.- Roche
Health Canada approves Tremfya to treat psoriatic arthritis.- Janssen Pharma
Novartis Tafinlar + Mekinist demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM.- Novartis
MIRROR open-label trial data published in Journal of Rheumatology shows 79 percent of gout patients achieved a complete response using Krystexxa with methotrexate.- Horizon Therapeutics
Study of Ajovy in migraine published in Neurology journal.- Teva Pharma
EU submission complete for Opdivo + Yervoy application to treat untreated, unresectable malignant pleural mesothelioma. - BMS
Orexo commences patent infringement litigation against Sun Pharmaceutical.
Recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-2 trial of baricitinib plus remdesivir.
Alexion and Caelum Biosciences announce start of phase III studies of CAEL 101 in AL amyloidosis.
Complete Response Letter for terlipressin to treat hepatorenal syndrome type 1.- Mallinckrodt
Seattle Genetics and Merck Inc., announce two strategic oncology collaborations affecting ladiratuzumab vedotin and tucatinib.
Novartis reports positive topline results from the first phase III trial of Beovu versus aflibercept in patients with diabetic macular edema (DME).
GEMINI Phase III trial of AXS 05 shows improved outcomes in depression.- Axsome Therapeutics
Vertex Pharmaceuticals applies at EMA for expanded indication of Kaftrio to treat cystic fibrosis in patients ages 12 years and older. .
Myovant Sciences presents additional data on bone mineral density in women with uterine fibroids from phase III LIBERTY program of relugolix combination therapy.
NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19.- BMS + Pfizer
Satsuma Pharmaceuticals announces topline results from EMERGE phase III trial of STS 101 nasal powder for the acute treatment of migraine.
COVID-19 vaccine AZD 1222 clinical trials resumed in the UK.- AstraZeneca
Study 402 positive results evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.-Intra-Cellular Therapies
Positive results from PEDFIC 1 trial of odevixibat to treat progressive familial intrahepatic cholestasis.- Albireo Pharma Inc.
Negative results from phase III RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis .- Corbus Pharmaceutical Holdings Inc.
Reyvow showed significant therapeutic gains of 17-21% for pain freedom at 2 hours and met all 18 gated endpoints. Eli Lilly
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug
Long-term disease control in Psoriasis: announcing a new project
Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease
